Two clinical trials reported in May 2026 suggest patients who lose weight using GLP-1 drugs can maintain results by switching to lower-dose injectable formulations or an oral pill called Foundayo without regaining lost mass immediately.
Investigators randomized participants who achieved target weight reduction on standard semaglutide doses into maintenance arms receiving reduced strength injections or daily oral therapy, comparing outcomes against placebo over multi-month follow-up.
Both strategies preserved average weight loss within statistical margins defined as clinically meaningful, though individual variability remained substantial. Oral options interest patients seeking to reduce injection burden and supply chain dependence on pens and needles.
Foundayo, described as an oral GLP-1 pathway agent, is undergoing regulatory review in multiple jurisdictions with sponsors citing convenience for long-term adherence. Lower-dose maintenance could also reduce gastrointestinal side effects that drive discontinuation in primary treatment phases.
Endocrinologists cautioned that lifestyle counseling and dietary monitoring remain essential adjuncts because pharmacologic maintenance does not eliminate caloric imbalance if habits revert. Insurance coverage for maintenance dosing remains inconsistent across payers.
Trial summaries appeared on Medical News Today alongside broader Memorial Day coverage of weight management science.
Insurance analysts said maintenance dosing coverage decisions will shape whether lower-strength GLP-1 regimens reach patients after initial weight-loss treatment phases conclude.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medicalnewstoday.com/news